Skip to content

Ketamine: all studies

Page 183 of 449: studies 1,821 to 1,830 of 4,486, newest first. Back to the ketamine overview

Research

The α2C-adrenoceptor antagonist JP-1302 controls behavioral parameters, tyrosine hydroxylase activity and receptor expression in a rat model of ketamine-induced schizophrenia-like deficits.

Pharmacology, Biochemistry, and Behavior November 1, 2022 Nurdan Tekin, Tuğba Karamahmutoğlu, A. Aykaç et al.

Schizophrenia is a chronic disabling disease affecting 1 % of the population. Current antipsychotics have limited efficacy in mitigating the severity of the symptoms of the disease. Therefore, searching for new therapeutic targets is essential. Previous studies have shown that α2C-adrenoceptor antagonists may have antipsychotic and pro-cognitive effects. Therefore, the current study evaluates...

S-ketamine exerts sex- and dose-dependent anti-compulsive-like effect as monotherapy or in augmentation to fluoxetine.

European Journal of Pharmacology November 1, 2022 Júlia Grigorini Mori Ayub, C. Tosta, Breno Lopes Macedo et al.

Since a significant body of studies supports the involvement of glutamatergic neurotransmission in the neurobiology of obsessive-compulsive disorder (OCD). Ketamine, a glutamate N-methyl-D-aspartate (NMDA) receptor antagonist with rapid and sustained antidepressant effect, raises as a potential new anti-OCD drug. Evidence from pre-clinical studies indicates that female mice are more sensitive...

Differential Alterations to the Metabolic Connectivity of the Cortical and Subcortical Regions in Rat Brain During Ketamine-Induced Unconsciousness.

Anesthesia & Analgesia November 1, 2022 Yali Chen, Siyang Li, Xia Liang et al.

Ketamine anesthesia increased glucose metabolism in most brain regions compared to another intravenous anesthetic propofol. However, whether the changes in cerebral metabolic networks induced by ketamine share the same mechanism with propofol remains to be explored. The purpose of the present study was to identify specific features of metabolic network in rat brains during ketamine-induced...

Ketamine as Potential Treatment for Postpartum Depression: A Narrative Review

Annals of Clinical Psychiatry November 1, 2022 David C J Chen-Li, Leanna M.W. Lui, Joshua D. Rosenblat et al. 22 citations

BACKGROUND: Postpartum depression (PPD) is a severe, debilitating mood disorder with consequences for both mothers and children, highlighting the need for rapid-acting and effective treatments for PPD. The aim of this narrative review is to synthesize the available literature on the administration of ketamine for PPD and propose ketamine as a viable and advantageous treatment. METHODS: A search...

DOI: 10.12788/acp.0082 (opens in new tab) Ketamine Depression economics Postpartum depression Psychotherapist +2

The therapeutic role of ketamine and esketamine in treating psychopathological domains of depression.

Neuropharmacology November 1, 2022 Muhammad Youshay Jawad, Joshua D. Di Vincenzo, Sebastian Badulescu et al. 29 citations

Over the past two decades, ketamine has emerged as a novel effective and safe rapid-acting antidepressant. While the vast majority of studies on ketamine have focused on its ability to reduce the severity of depression broadly, its effectiveness in specific domains such as cognition, anhedonia, suicidality, and workplace/social/scholastic functionality has been neglected. Similarly, current...

Maintenance ketamine treatment for depression: a systematic review of efficacy, safety, and tolerability.

The Lancet Psychiatry November 1, 2022 Sanne Y Smith-Apeldoorn, Jolien K E Veraart, Jan Spijker et al. 163 citations

Ketamine has rapid yet often transient antidepressant effects in patients with treatment-resistant depression. Different strategies have been proposed to prolong these effects. Maintenance ketamine treatment appears promising, but little is known about its efficacy, safety, and tolerability in depression. We searched Pubmed, Embase, and the Cochrane Library and identified three randomised...

Safety of Ketamine Augmentation to Monoamine Oxidase Inhibitors in Treatment-Resistant Depression: A Systematic Literature Review and Case Series.

The Journal of Clinical Psychiatry October 24, 2022 Jolien K E Veraart, Sanne Y Smith-Apeldoorn, M. Kutscher et al.

Objective: Ketamine is increasingly prescribed for treatment-resistant depression (TRD), often as add-on to regular antidepressants. Augmentation of ketamine to monoamine oxidase inhibitors (MAOIs) is advised against, as this practice might increase blood pressure or cause serotonin syndrome. Despite the potential relevance for patients, little is known about actual side effects of combined...

Subthreshold repetitive transcranial magnetic stimulation suppresses ketamine-induced poly population spikes in rat sensorimotor cortex

Frontiers in Neuroscience October 21, 2022 Wenxuan Jiang, Robert Isenhart, Robert L. Sutherland et al. 5 citations

Cortical oscillations within or across brain regions play fundamental roles in sensory, motor, and memory functions. It can be altered by neuromodulations such as repetitive transcranial magnetic stimulation (rTMS) and pharmacological manipulations such as ketamine. However, the neurobiological basis of the effects of rTMS and ketamine, as well as their interactions, on cortical oscillations is...

Efficacy and Safety of Ketamine vs Electroconvulsive Therapy Among Patients With Major Depressive Episode: A Systematic Review and Meta-analysis.

JAMA Psychiatry October 19, 2022 T. Rhee, S. Shim, B. Forester et al. 139 citations

Importance Whether ketamine is as effective as electroconvulsive therapy (ECT) among patients with major depressive episode remains unknown. Objective To systematically review and meta-analyze data about clinical efficacy and safety for ketamine and ECT in patients with major depressive episode. Data Sources PubMed, MEDLINE, Cochrane Library, and Embase were systematically searched using...

Active mechanisms of ketamine-assisted psychotherapy: A systematic review.

Journal of Affective Disorders October 15, 2022 Isak Joneborg, Yena Lee, Joshua D. Di Vincenzo et al.

Few studies have evaluated the efficacy of ketamine-assisted psychotherapy (KAP) in the treatment of treatment-resistant depression (TRD) and substance use disorders (SUD). A systematic review of clinical trials reporting on the efficacy of KAP and discussing mechanisms of action, identified on PubMed and PsycInfo. Five randomized-controlled trials reported on the efficacy of KAP treatment and...